Tag : journal

AI/ML

AB InBev Taps Machine Learning to Root Out Corruption – Wall Street Journal

Newsemia
AB InBev Taps Machine Learning to Root Out Corruption  Wall Street Journal Source link...
Latest News

Russian Investigation Retracts More Than 800 Scientific Papers Due To Issues

Newsemia
In recent news, academic journals in Russia are reportedly retracting more or less 800 papers after a probe by a commission appointed by the Russian...
Latest News

Scientific Journal Names Black Hole Photo Top Science Breakthrough Of 2019

Newsemia
Previously thought to be impossible, the first ever captured photo of a black hole has recently been named the top science breakthrough of 2019. Source...
Cardiology

Corrigendum to 'Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia' [European Journal of Vascular & Endovascular Surgery 58/1S (2019) 1-109].

Newsemia
Related Articles Corrigendum to ‘Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia’ [European Journal of Vascular & Endovascular Surgery 58/1S (2019) 1-109]. Eur...
Latest News

Samenvatting: Resultaten van Fase III SAkuraSky-studie voor Chugai’s Satralizumab bij Neuromyelitis Optica Spectrumstoornis Gepubliceerd in The New England Journal of Medicine Online

Newsemia
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) heeft aangekondigd dat de resultaten van de SAkuraSky-studie (NCT02028884), een wereldwijde fase III klinische studie van satralizumab (ontwikkelingscode:...
Latest News

Positive Phase III Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in the New England Journal of Medicine

Newsemia
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that data from SAkuraSky, a pivotal Phase...
Latest News

Die Ergebnisse der Phase-III-SAkuraSky-Studie für Chugai Satralizumab bei Neuromyelitis-optica-Spektrum-Erkrankungen wurden im New England Journal of Medicine Online veröffentlicht

Newsemia
TOKIO (Japan)–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) gab bekannt, dass die Ergebnisse der SAkuraSky-Studie (NCT02028884), einer globalen klinischen Phase-III-Studie zu Satralizumab (Entwicklungscode: SA237), am...
Latest News

Les résultats d’une étude SAkuraSky de phase III portant sur le satralizumab de Chugai pour la maladie du spectre de la neuromyélite optique ont été publiés en ligne dans le New England Journal of Medicine

Newsemia
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO : 4519) a annoncé que les résultats de l’étude SAkuraSky (NCT02028884), une étude clinique mondiale de phase III portant sur le satralizumab (code...
Cardiology

Optimizing The Management of Obese HFpEF Phenotype: Can We Mind Both The Heart and The Kidney?: Invited Editorial Commentary for Journal of Cardiac Failure.

Newsemia
Related Articles Optimizing The Management of Obese HFpEF Phenotype: Can We Mind Both The Heart and The Kidney?: Invited Editorial Commentary for Journal of Cardiac...
Latest News

First Head-to-Head Biologic Study in Ulcerative Colitis Published in The New England Journal of Medicine Highlights Benefit of Vedolizumab vs. Adalimumab

Newsemia
OSAKA, Japan–(BUSINESS WIRE)–Published in NEJM, further results from the VARSITY study which demonstrated the superiority of the gut-selective biologic vedolizumab to adalimumab Source link...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy